Summary
AD remains one of our greatest unmet medical needs, without any approved disease-modifying therapies. Individuals with DS comprise the largest group with genetically determined AD. We propose to assess the utility of Tau PET imaging as well as CSF and blood levels of Ptau217 as outcome measures for clinical trials of AD in adults with DS.
Down Syndrome Publications
The journal of prevention of Alzheimer's disease2021